Distinct Impact of Phosphodiesterade-4 (PDE4) Inhibition in Two Pre-clinical Psoriasis Models

Pharmindex [Internet]. [cited 2024 Aug 12]. Available from: http://www.gelbe-liste.de

Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001; 297: 267–279.

https://doi.org/10.1016/S0022-3565(24)29537-9 DOI: https://doi.org/10.1016/S0022-3565(24)29537-9

Man H wah, Schafer P, Wong LM, Patterson RT, Corral LG, Raymon H, et al. Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxy-(Apremilast ), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. J Med Chem 2009; 52: 1522–1524.

https://doi.org/10.1021/jm900210d DOI: https://doi.org/10.1021/jm900210d

Walsh NM. Comparison of the modes of action of Apremilast and Roflumilast. Enlighten thesxes. Glasgow: University of Glasgow; 2015.

Gyldenløve M, Meteran H, Sørensen JA, Fage S, Yao Y, Lindhardsen J, et al. Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis-a randomized controlled trial (PSORRO). Lancet Reg Health – Eur 2023; 30: 100639.

https://doi.org/10.1016/j.lanepe.2023.100639 DOI: https://doi.org/10.1016/j.lanepe.2023.100639

Swindell WR, Johnston A, Carbajal S, Han G, Wohn C, Lu J, et al. Genome-wide expression profiling of five mouse models identifies similarities and differences with human psoriasis. PLoS ONE 2011; 6: e18266.

https://doi.org/10.1371/journal.pone.0018266 DOI: https://doi.org/10.1371/journal.pone.0018266

Fits LVD, Mourits S, Voerman JSA, Kant M, Boon L, Laman JD, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009; 182: 5836–5845.

https://doi.org/10.4049/jimmunol.0802999 DOI: https://doi.org/10.4049/jimmunol.0802999

Gauld SB, Gauvin D, Olson L, Leys L, Paulsboe S, Liu Z, et al. Mechanistic and pharmacological assessment of murine IL-23 mediated psoriasiform dermatitis: implications for drug discovery. J Dermatol Sci 2018; 92: 45–53.

https://doi.org/10.1016/j.jdermsci.2018.08.001 DOI: https://doi.org/10.1016/j.jdermsci.2018.08.001

Bieber K, Bezdek S, Gupta Y, Vorobyev A, Sezin T, Gross N, et al. Forward genetics and functional analysis highlight Itga11 as a modulator of murine psoriasiform dermatitis. J Pathol 2023; 261: 184–197.

https://doi.org/10.1002/path.6162 DOI: https://doi.org/10.1002/path.6162

Dräger S, Kalies K, Sidronio TB, Witte M, Ludwig RJ, Bieber K. Increased TREM-1 expression in inflamed skin has no functional impact on the pathogenesis of cutaneous disorders. J Dermatol Sci 2017; 88: 139–155.

https://doi.org/10.1016/j.jdermsci.2017.05.016 DOI: https://doi.org/10.1016/j.jdermsci.2017.05.016

Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006; 203: 2577–2587.

https://doi.org/10.1084/jem.20060244 DOI: https://doi.org/10.1084/jem.20060244

Xu R, Feng S, Ao Z, Chen Y, Su C, Feng X, et al. Long-acting β2 adrenergic receptor agonist ameliorates imiquimod-induced psoriasis-like skin lesion by regulating keratinocyte proliferation and apoptosis. Front Pharmacol 2022; 13: 865715.

https://doi.org/10.3389/fphar.2022.865715 DOI: https://doi.org/10.3389/fphar.2022.865715

Uchida H, Kamata M, Shimizu T, Egawa S, Ito M, Takeshima R, et al. Apremilast downregulates interleukin-17 production and induces splenic regulatory B cells and regulatory T cells in imiquimod-induced psoriasiform dermatitis. J Dermatol Sci 2021; 104: 55–62.

https://doi.org/10.1016/j.jdermsci.2021.08.001 DOI: https://doi.org/10.1016/j.jdermsci.2021.08.001

Ernst O, Failayev H, Athamna M, He H, Tsfadia Y, Zor T. A dual and conflicting role for imiquimod in inflammation: a TLR7 agonist and a cAMP phosphodiesterase inhibitor. Biochem Pharmacol 2020; 182: 114206.

https://doi.org/10.1016/j.bcp.2020.114206 DOI: https://doi.org/10.1016/j.bcp.2020.114206

Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KHG. Interleukin-1 and IL-23 induce innate IL-17 production from γδ t cells, amplifying Th17 responses and autoimmunity. Immunity 2009; 31: 331–341.

https://doi.org/10.1016/j.immuni.2009.08.001 DOI: https://doi.org/10.1016/j.immuni.2009.08.001